Cardiovascular effects and pharmacokinetics of nebivolol were assessed in spontaneously hypertensive rats (SHR) and Wistar Kyoto (WKY) animals. Male SH and WKY rats were treated with vehicle or nebivolol 0.3, 3, or 10 mg kg−1 (i.v.) and effects on blood pressure (BP), heart rate, and blood pressure variability (BPV) were recorded. Plasma pharmacokinetics of d- and l-nebivolol was studied by traditional blood sampling. Short-term and beat-to-beat BPV was assessed by standard deviation and spectral analysis of BP recording, respectively. Nebivolol showed enantioselective pharmacokinetics in both experimental groups; clearance of l-nebivolol was significantly greater than d-enantiomer. Clearance of nebivolol was significantly reduced in SHR wi...
Abstractβ-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular medication...
BackgroundThe exploration of Blood Pressure (BP) variability and of the influence of different antih...
Arterial stiffness is a key determinant of cardiovascular risk in hypertensive patients. [beta]-Bloc...
The cardiovascular effects and pharmacokinetics of nebivolol were assessed in N(G)-nitro-l-arginine ...
The cardiovascular and pharmacokinetic effects of nebivolol were evaluated in hypertensive fructose-...
In the pithed rat we investigated the cardiovascular properties of d,l-nebivolol and its enantiomers...
An increase in blood pressure variability (BPV) contributes to the development of target organ damag...
Nebivolol (R67555), a drug with beta-1 receptor antagonizing properties, was administered once daily...
In the pithed normotensive rat, the effects of dl-nebivolol and its enantiomers on the (-)-adrenalin...
β-Adrenergic blockers are no longer recommended as first-line therapy due to the reduced cardioprote...
Background: b-blockers are no longer considered as firstline antihypertensive drugs due to their low...
BACKGROUND: Although effective in reducing blood pressure, therapy with a first-generation [beta]-bl...
The importance of chronic stimulation of β-adrenoceptors in the development of cardiac dysfunction i...
Nebivolol is a new selective beta 1-adrenoceptor antagonist with nitric oxide (NO)–releasing propert...
Nebivolol is a highly selective β1 adrenoceptor blocker available clinically and is devoid of int...
Abstractβ-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular medication...
BackgroundThe exploration of Blood Pressure (BP) variability and of the influence of different antih...
Arterial stiffness is a key determinant of cardiovascular risk in hypertensive patients. [beta]-Bloc...
The cardiovascular effects and pharmacokinetics of nebivolol were assessed in N(G)-nitro-l-arginine ...
The cardiovascular and pharmacokinetic effects of nebivolol were evaluated in hypertensive fructose-...
In the pithed rat we investigated the cardiovascular properties of d,l-nebivolol and its enantiomers...
An increase in blood pressure variability (BPV) contributes to the development of target organ damag...
Nebivolol (R67555), a drug with beta-1 receptor antagonizing properties, was administered once daily...
In the pithed normotensive rat, the effects of dl-nebivolol and its enantiomers on the (-)-adrenalin...
β-Adrenergic blockers are no longer recommended as first-line therapy due to the reduced cardioprote...
Background: b-blockers are no longer considered as firstline antihypertensive drugs due to their low...
BACKGROUND: Although effective in reducing blood pressure, therapy with a first-generation [beta]-bl...
The importance of chronic stimulation of β-adrenoceptors in the development of cardiac dysfunction i...
Nebivolol is a new selective beta 1-adrenoceptor antagonist with nitric oxide (NO)–releasing propert...
Nebivolol is a highly selective β1 adrenoceptor blocker available clinically and is devoid of int...
Abstractβ-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular medication...
BackgroundThe exploration of Blood Pressure (BP) variability and of the influence of different antih...
Arterial stiffness is a key determinant of cardiovascular risk in hypertensive patients. [beta]-Bloc...